文章名稱引用次數(shù)

• Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data60
• Safety and efficacy of tofacitinib for up to 9.5years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study39
• Synovial fluid biomarkers associated with osteoarthritis severity reflect macrophage and neutrophil related inflammation28
• NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis25
• Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)24
• Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study22
• CCL17 blockade as a therapy for osteoarthritis pain and disease22
• The impact of dysfunctional variants of ABCG2 on hyperuricemia and gout in pediatric-onset patients22
• IL-17A induces osteoblast differentiation by activating JAK2/STAT3 in ankylosing spondylitis21
• Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations21